Cencora to Buy American Oncology Network in $2.4 Billion Community Oncology Push
What happened Cencora, the US pharmaceutical distribution and services group, has signed a definitive agreement to acquire American Oncology Network, a Fort Myers, Florida based physician-led network of more than 350 oncology providers practicing across 21 states. The deal was announced on 21 October 2026 and values AON at an enterprise value of $2.4 billion. […]
Alcon Buys Neurotech for $550 Million to Add First Approved MacTel Eye Therapy
What happened Alcon, the Geneva-based eye care group, has acquired Neurotech Pharmaceuticals, a private US biotech, for $550 million in cash, with further contingent payments possible if commercial milestones are met. The deal was announced and completed on 20 October 2026. It gives Alcon ENCELTO, an encapsulated cell therapy that is the first and only […]
Mankind Pharma Buys 70% of Armed Cell Therapeutics for 48 Million Euros to Enter Next-Generation CAR-T
What happened Mankind Pharma, the New Delhi-based drugmaker, has agreed to acquire a 70 percent stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated biotechnology company developing next-generation CAR-T cell therapies for cancer. The company announced the definitive agreement on 15 October 2026. Mankind will invest EUR 48 million for the stake, paid in installments, […]
Labcorp to Buy Select BioReference Health Assets from OPKO for Up to $872 Million
What happened Labcorp and OPKO Health have agreed that Labcorp will acquire select assets of BioReference Health, a wholly owned OPKO subsidiary. The companies announced the deal on 15 October 2026. The purchase price is $722 million in cash at closing, subject to an upward or downward adjustment tied to closing business revenues, plus up […]
Galderma to Buy ZO Skin Health for $1.5 Billion to Expand Physician-Dispensed Skincare
What happened Galderma, the Swiss-listed pure-play dermatology group, announced on 14 October 2026 that it has signed an agreement to acquire 100% of ZO Skin Health, the Irvine, California physician-dispensed skincare brand, for an enterprise value of $1.5 billion. The sellers include funds managed by Blackstone Tactical Opportunities and the Obagi family. The deal is […]
Agilent to Buy Proscia for $240 Million to Own the Digital Pathology Software Layer
What happened Agilent Technologies said on 13 October 2026 that it has signed a definitive agreement to acquire Proscia, a digital pathology software company, for $240 million in cash at closing. Up to $30 million more is payable if Proscia hits future performance milestones. The deal is expected to close early in Agilent fiscal year […]
CD&R and McKesson Agree to Buy Option Care Health for $5.8B in Home Infusion Bet
CD&R and McKesson have agreed to take Option Care Health private for $32.05 per share, an enterprise value of about $5.8 billion and a premium of roughly 37% to the October 5 close. CD&R will own about 51% and McKesson will put in about $1.4 billion for the remaining 49%, with a built-in framework for […]
Viatris to Acquire Pacira BioSciences in $1.65 Billion Non-Opioid Pain Bet
Viatris has agreed to buy Pacira BioSciences for USD 36.50 per share in cash, an equity value of roughly USD 1.65 billion. The structure is a tender offer followed by a short-form merger, and both companies are pointing to completion by the end of 2026. It is a statement about where a large generics-heavy company […]
Ofichem to Acquire Kinentia Biosciences in Transatlantic Drug Substance CDMO Push
What happened Ofichem, the Dutch pharmaceutical services group, has signed an agreement to acquire Kinentia Biosciences, a drug substance contract development and manufacturing organization (CDMO) based in Rensselaer, New York. No financial terms were disclosed. Completion depends on clearance from the Committee on Foreign Investment in the United States (CFIUS) and other customary conditions. The […]
GE HealthCare to Acquire SOFIE Biosciences for $945M to Own PET Tracer Supply
What happened On 5 October 2026, GE HealthCare signed a definitive agreement to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from private equity owner Trilantic North America for $945 million in cash. Closing is expected in the first half of 2027, subject to regulatory approvals, after which SOFIE will sit inside the […]